According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

With Merck & Co. largely propping up supplies of the bladder cancer-fighting bacteria Bacillus Calmette-Guérin (BCG) in the U.S., ImmunityBio has received the FDA all-clear to help pick up the ...

New facility will manufacture HPV vaccines Gardasil and Gardasil 9. Merck plans to invest $8 billion more in U.S. by 2028. A ...

Merck says the expansion in Durham is part of more than $12 billion the company has invested in U.S. manufacturing and ...

while Merck & Co., based in New Jersey, currently is the only manufacturer of BCG (TICE® BCG) in the U.S. ImmunityBio has been awarded multiple patents covering the composition and methods of use ...

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated ...

while Merck & Co., based in New Jersey, currently is the only manufacturer of BCG (TICE® BCG) in the U.S. ImmunityBio has been awarded multiple patents covering the composition and methods of ...

while Merck & Co., based in New Jersey, currently is the only manufacturer of BCG (TICE® BCG) in the U.S. ImmunityBio has been awarded multiple patents covering the composition and methods of use ...

This program will provide patients in the U.S. with a critical alternative source of BCG, a standard-of-care treatment for bladder cancer. ImmunityBio said that Merck’s TICE BCG shortages have ...